An Early Phase 1 interventional study of Aspirin and Placebo in Preeclampsia, sponsored by Anna Stanhewicz, PhD. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-12-15.
Sponsored by Anna Stanhewicz, PhD · Early Phase 1, Interventional, and Basic science
Women who develop preeclampsia during pregnancy are four times more likely to develop cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs may be related to lasting blood vessel damage after the pregnancy but there are currently no specific treatment strategies to prevent this disease progression. This study addresses this public health issue by examining whether starting low dose aspirin therapy after pregnancy is an effective treatment for lasting blood vessel damage in order to inform better clinical management of cardiovascular disease risk in women who have had preeclampsia.
882 studies on the registry are indexed under Pre-Eclampsia; 237 are open to participants now.
This study's planned enrollment of 40 is below the median of 110 across 468 interventional studies indexed under Pre-Eclampsia.
Browse Pre-Eclampsia studies →Anna Stanhewicz, PhD is the lead sponsor of 15 studies on the registry; 10 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion criteria:
placebo pill taken once daily at bedtime for 12 weeks
Drug: Placebo
162mg aspirin taken once daily at bedtime for 12 weeks
Drug: Aspirin
162mg aspirin capsule
placebo capsule
magnitude of microvascular endothelial function
skin blood flow response to acetylcholine delivered via intradermal microdialysis
Time frame: baseline, 12 weeks
magnitude of brachial artery endothelial function
brachial artery flow mediated dilation
Time frame: baseline, 12 weeks
magnitude of microvascular endothelin-1 mediated constriction
skin blood flow response to endothelin-1 delivered via intradermal microdialysis
Time frame: baseline, 12 weeks
magnitude of microvascular nitric oxide-dependent dilation
skin blood flow response to acetylcholine + L-NAME delivered via intradermal microdialysis
Time frame: baseline, 12 weeks
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Anna Stanhewicz, PhD